# ğŸ« Pulmonary Medicine: Step-Up Therapy in Persistent Asthma

#### âœ… True Statements
1. The **National Asthma Education and Prevention Program (NAEPP) 2020 guidelines** recommend that adults with **moderate persistent asthma** use a **single combined glucocorticoid-formoterol inhaler daily with additional doses as needed** (maintenance and reliever therapy, MART).  
2. For step-up therapy in **poorly controlled asthma**, use **medium- to high-dose combined inhaled glucocorticoidâ€“long-acting Î²2-agonist (LABA)** plus a **long-acting muscarinic antagonist (LAMA)** and **short-acting Î²2-agonist as needed**, if no contraindications exist.  
3. In patients with **persistent asthma poorly controlled on medium-dose budesonide-formoterol**, the next step is to **increase to high-dose budesonide-formoterol**.  
4. **Antiâ€“interleukin-5 therapy** (e.g., **mepolizumab**) can be considered for patients with **absolute eosinophil count >150/ÂµL (0.15 Ã— 10â¹/L)** but is not indicated for patients with lower counts.  
5. **Anti-IgE therapy** (e.g., **omalizumab**) is considered in patients with **perennial allergen sensitivity** and **IgE 30â€“700 U/mL**, but only after failure of **high-dose inhaled glucocorticoidâ€“LABA therapy**.  
6. **LAMAs (e.g., tiotropium)** can improve lung function and reduce exacerbations in asthma uncontrolled on **glucocorticoidâ€“LABA therapy**, but they should be **avoided in patients at risk for urinary retention**.  

#### ğŸ’¬ Extra
1. MART improves adherence and reduces exacerbations compared to separate maintenance + rescue inhalers.  
4. This patientâ€™s eosinophil count of 120/ÂµL does not meet the threshold for IL-5 biologics.  
6. Urinary retention risk is important in patients with **benign prostatic hyperplasia (BPH)**.  

#### ğŸ·ï¸ Tags
#Asthma #StepUpTherapy #MART #Glucocorticoid #LABA #LAMA #Biologics  

#### ğŸ“š Reference
Cloutier MM, Baptist AP, Blake KV, et al; Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC). 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. *J Allergy Clin Immunol*. 2020;146:1217-70. PMID: 33280709 doi:10.1016/j.jaci.2020.10.003  

#### ğŸ†” Question ID
PMMCQ24041  

#### ğŸ•’ Last Updated
February 2025  

---

#### ğŸ“– Related Text
MKSAP 19: Pulmonary Medicine â€” Airways Disease, Asthma, Management of Chronic Asthma, Controller Medications for Asthma  

---

### ğŸ“˜ Related Text Derivations

#### âœ… True Statements â€” Controller Medications for Asthma
1. **Inhaled glucocorticoids** are the most effective class of **controller medications** in asthma.  
2. **Active smoking** reduces the effectiveness of inhaled glucocorticoids and may require higher doses.  
3. **Adverse effects of inhaled glucocorticoids** include **oral candidiasis, dysphonia**, and, at higher doses, **systemic effects** such as **adrenocortical suppression, reduced bone mineral density, cataracts, and increased pneumonia risk**.  
4. **LABAs** improve control and reduce exacerbations when combined with inhaled glucocorticoids, but **should not be used alone** because of increased risk of asthma-related death.  
5. **LABAs plus inhaled glucocorticoids in a single inhaler** improve adherence and reduce cost compared with separate inhalers.  
6. **Leukotriene receptor antagonists** have modest bronchodilation effects and are effective in **aspirin-exacerbated respiratory disease**.  
7. **Oral glucocorticoids** should be reserved for acute exacerbations and **avoided long term** due to adverse effects.  
8. **LAMAs (e.g., tiotropium)** improve lung function and reduce exacerbations when added to inhaled glucocorticoidâ€“LABA therapy.  
9. **Biologic therapies** (anti-IgE, anti-IL-5, anti-IL-4/IL-13, anti-TSLP) are used in **severe asthma not adequately controlled on standard therapy**.  
10. **Omalizumab** reduces exacerbations and emergency visits in patients with **moderate to severe atopic asthma** not controlled with high-dose inhaled glucocorticoidâ€“LABA therapy.  
11. **IL-5 inhibitors (mepolizumab, reslizumab, benralizumab)** and **IL-4/IL-13 inhibitor (dupilumab)** benefit patients with **eosinophilia** (threshold 150â€“400/ÂµL depending on agent).  
12. **Tezepelumab**, an anti-TSLP biologic, is approved for **severe asthma regardless of phenotype**.  
13. Before biologics, clinicians must verify **adherence**, assess **inhaler technique**, and address **comorbidities**.  

#### ğŸ’¬ Extra
3. Systemic effects are uncommon below **400 Âµg/day budesonide equivalent**.  
4. LABAs are safe when combined with inhaled glucocorticoids (as confirmed in large trials).  
12. Tezepelumab has a broader indication than other biologics because it is not limited to eosinophilic or allergic asthma phenotypes.  

#### ğŸ·ï¸ Tags
#Asthma #ControllerMedications #InhaledGlucocorticoids #LABA #LAMA #LeukotrieneAntagonists #Biologics  

---

#### ğŸ—¾ Supplemental Tables

<table>
  <caption><strong>Characteristics of Biologic Agents Indicated to Treat Severe Asthma</strong></caption>
  <thead>
    <tr>
      <th>Biologic Agent</th>
      <th>Target</th>
      <th>Guidelines<sup>b</sup></th>
      <th>Formulation</th>
      <th>Home Use</th>
      <th>Adverse Effects</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Omalizumab</td>
      <td>IgE</td>
      <td>Severe asthma, IgE 30 to 700 U/mL (30-700 kU/L) and atopy</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Anaphylaxis, increased risk of malignancy</td>
    </tr>
    <tr>
      <td>Mepolizumab</td>
      <td>IL-5</td>
      <td>Severe asthma, absolute eosinophils >150/ÂµL (0.15 Ã— 10<sup>9</sup>/L)</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions, headache, helminth infections</td>
    </tr>
    <tr>
      <td>Reslizumab</td>
      <td>IL-5</td>
      <td>Severe asthma, absolute eosinophils >400/ÂµL (0.4 Ã— 10<sup>9</sup>/L)</td>
      <td>Intravenous infusion</td>
      <td>No</td>
      <td>Anaphylaxis, headache, helminth infections</td>
    </tr>
    <tr>
      <td>Benralizumab</td>
      <td>IL-5</td>
      <td>Severe asthma, absolute eosinophils >150/ÂµL (0.15 Ã— 10<sup>9</sup>/L)</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions, helminth infections</td>
    </tr>
    <tr>
      <td>Dupilumab</td>
      <td>IL-4, IL-13</td>
      <td>Moderate to severe asthma, absolute eosinophils >150/ÂµL (0.15 Ã— 10<sup>9</sup>/L) or dependence on systemic glucocorticoids</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions, helminth infections</td>
    </tr>
    <tr>
      <td>Tezepelumab</td>
      <td>TSLP</td>
      <td>Severe asthma, add-on therapy</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions</td>
    </tr>
  </tbody>
</table>
<p><em>IL = interleukin; TSLP = thymic stromal lymphopoietin.<br>
aSpecialty referral recommended.<br>
bPatients with severe asthma not adequately controlled on standard therapy.</em></p>

---

#### âœ… True Statements (from Table: Characteristics of Biologic Agents Indicated to Treat Severe Asthma)
1. **Omalizumab** targets **IgE**, is used in **severe asthma with IgE 30â€“700 U/mL and atopy**, is given by **subcutaneous injection**, and carries a risk of **anaphylaxis and malignancy**.  
2. **Mepolizumab** targets **IL-5**, is indicated for **severe asthma with eosinophils >150/ÂµL**, is given by **subcutaneous injection**, and may cause **hypersensitivity, headache, or helminth infections**.  
3. **Reslizumab** targets **IL-5**, is indicated for **severe asthma with eosinophils >400/ÂµL**, is given by **intravenous infusion**, and may cause **anaphylaxis, headache, or helminth infections**.  
4. **Benralizumab** targets **IL-5**, is indicated for **severe asthma with eosinophils >150/ÂµL**, is given by **subcutaneous injection**, and may cause **hypersensitivity or helminth infections**.  
5. **Dupilumab** targets **IL-4 and IL-13**, is indicated for **moderate to severe asthma with eosinophils >150/ÂµL or glucocorticoid dependence**, is given by **subcutaneous injection**, and may cause **hypersensitivity or helminth infections**.  
6. **Tezepelumab** targets **TSLP**, is indicated as **add-on therapy for severe asthma regardless of phenotype**, is given by **subcutaneous injection**, and may cause **hypersensitivity reactions**.  

#### ğŸ·ï¸ Tags
#Asthma #Biologics #Omalizumab #Mepolizumab #Reslizumab #Benralizumab #Dupilumab #Tezepelumab  
